| DIRECT COMPETITOR COMPARISON | |
| DEPO | BMY | JNJ | TEVA | Industry | | Market Cap: | 170.08M | 50.14B | 173.38B | 46.51B | 161.24M | | Employees: | 81 | 35,000 | 118,700 | 38,307 | 103 | | Qtrly Rev Growth (yoy): | 63.10% | 4.40% | -5.30% | 24.90% | 20.50% | | Revenue (ttm): | 53.21M | 21.14B | 60.53B | 12.95B | 46.74M | | Gross Margin (ttm): | 17.88% | 72.39% | 71.08% | 55.30% | 68.58% | | EBITDA (ttm): | -28.72M | 6.32B | 19.05B | 3.94B | -7.12M | | Oper Margins (ttm): | -55.94% | 26.65% | 26.94% | 24.35% | 2.25% | | Net Income (ttm): | -29.63M | 3.79B | 12.77B | 953.00M | N/A | | EPS (ttm): | -0.578 | 1.933 | 4.579 | 1.093 | -0.17 | | P/E (ttm): | N/A | 13.09 | 13.72 | 48.30 | 17.12 | | PEG (5 yr expected): | N/A | 2.51 | 1.85 | 0.98 | 1.04 | | P/S (ttm): | 3.16 | 2.38 | 2.87 | 3.60 | 4.17 |
|
| BMY = Bristol-Myers Squibb Co. | | JNJ = Johnson & Johnson | | TEVA = Teva Pharmaceutical Industries Limited | | Industry = Drug Manufacturers - Other | |
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 56.35 | -0.27% | 57.03B | 12.29 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 46.94 | 0.04% | 13.57B | 15.71 | | Genzyme Corp. | GENZ | 50.70 | -0.72% | 13.45B | 28.91 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.11 | -0.97% | 41.50B | 17.83 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 49.78 | -0.34% | 8.88B | 1015.92 | | Teva Pharmaceutical Industries Limited | TEVA | 52.79 | -0.17% | 46.51B | 48.30 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 37.09 | 0.35% | 3.94B | 19.12 | | Barr Pharmaceuticals, Inc. | Private - View Profile | | King Pharmaceuticals Inc. | KG | 11.83 | -1.00% | 2.94B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 17.87 | -0.78% | 5.46B | 109.63 | | Pfizer Inc. | PFE | 18.17 | -0.44% | 146.62B | 15.09 | | Johnson & Johnson | JNJ | 62.84 | -0.08% | 173.38B | 13.72 | | GlaxoSmithKline plc | GSK | 41.47 | -1.87% | 105.13B | 13.17 | | Sanofi-Aventis | SNY | 37.96 | -1.22% | 99.12B | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Novartis AG | NVS | 55.60 | 0.40% | 126.28B | 16.65 | | RHHBY.PK | 40.92 | -1.30% | N/A | N/A | | AstraZeneca plc | AZN | 44.83 | -1.02% | 65.00B | 9.00 | | Abbott Laboratories | ABT | 54.49 | 0.76% | 84.28B | 14.76 | | Bristol-Myers Squibb Co. | BMY | 25.31 | -0.28% | 50.14B | 13.09 |
|
| NEWS ON DIRECT COMPETITORS | |
|
|
|